文献速递消化系统肿瘤

多西他赛、顺铂和氟尿嘧啶化疗用于转移性或不可切除局部复发性肛管鳞状细胞癌(Epitopes-HPV02):一项多中心、单臂、2期研究

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
PubMed 文献 · Lancet Oncol · 2018-07-02

这项多中心单臂2期研究评估了DCF方案一线治疗转移性或不可切除局部复发性肛管鳞状细胞癌的疗效与安全性。66例接受治疗患者中,12个月无进展生存率为47%,达到主要终点。标准DCF组3-4级不良事件发生率为83%,高于改良DCF组的53%,改良DCF耐受性更好。

要点

  • 改良DCF方案在ECOG 0-1分患者中显示出持久缓解且耐受性良好。
  • 标准DCF因高级别和严重不良事件及发热性中性粒细胞减少风险较高,不推荐使用。
  • 改良DCF可考虑作为转移性或不可切除局部复发性肛管鳞癌一线治疗的新标准。

核心结论

  • 与标准DCF相比,改良DCF在ECOG评分0-1的转移性或不可切除局部复发性肛管鳞状细胞癌一线治疗中提供持久缓解且耐受性良好,可考虑作为新的标准治疗。
  • 鉴于高级别和严重不良事件及发热性中性粒细胞减少风险升高,标准DCF在此情况下不予推荐。

研究设计与样本

  • 多中心、单臂、2期研究,在法国25家学术医院、癌症研究中心和社区医院招募患者。
  • 入组标准为年龄≥18岁、组织学确诊肛管鳞状细胞癌、转移性疾病或不可切除局部复发、ECOG评分0或1、至少一个可评估病灶。
  • 化疗初治患者接受6周期标准DCF(多西他赛75 mg/m2和顺铂75 mg/m2第1天,氟尿嘧啶750 mg/m2/天持续5天,每3周)或8周期改良DCF(多西他赛40 mg/m2和顺铂40 mg/m2第1天,氟尿嘧啶1200 mg/m2/天持续2天,每2周)。
  • 主要终点为研究者评估的12个月无进展生存率,需至少11例(17%)患者12个月时存活且无进展。
  • 2014年9月17日至2016年12月7日共入组69例患者,66例接受治疗并纳入改良意向治疗分析。

主要发现

  • 66例接受治疗患者中,31例(47%)在12个月时存活且无进展,达到主要终点。
  • 标准DCF组36例中22例(61%)和改良DCF组30例中18例(60%)在数据截止时出现疾病进展。
  • 66例中46例(70%)发生至少一次3-4级不良事件,标准DCF组为30/36(83%),改良DCF组为16/30(53%)。
  • 常见3-4级不良事件包括中性粒细胞减少15例(23%)、腹泻12例(18%)、乏力10例(15%)、贫血10例(15%)等。
  • 改良DCF组未观察到4级非血液学不良事件和发热性中性粒细胞减少,标准DCF组分别报告3例(8%)和5例(14%)。

关键数值与推荐

  • 主要终点达到:31/66例(47%)12个月无进展生存,超过预设阈值11/66(17%)。
  • 标准DCF组3-4级不良事件发生率83%(30/36),改良DCF组53%(16/30)。
  • 标准DCF组发热性中性粒细胞减少5例(14%),改良DCF组0例。
  • 未记录治疗相关死亡。

临床怎么用

  • 对于ECOG评分0-1的转移性或不可切除局部复发性肛管鳞状细胞癌一线患者,可优先考虑改良DCF方案。
  • 标准DCF因毒性较高不推荐用于该人群。
  • 治疗选择可基于年龄和ECOG评分等因素考虑标准或改良方案。

局限性

  • 单臂设计,无随机对照。
  • 样本量较小(66例接受治疗)。
  • 主要终点为研究者评估,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of anal squamous cell carcinoma has been increasing markedly in the past few decades. Currently, there is no validated treatment for advanced-stage anal squamous cell carcinoma. Therefore, we aimed to validate the clinical activity and safety of docetaxel, cisplatin, and fluorouracil (DCF) chemotherapy in patients with metastatic or unresectable locally recurrent anal squamous cell carcinoma. METHODS: We did a multicentre, single-arm, phase 2 study. We recruited patients from 25 academic hospitals, cancer research centres, and community hospitals in France who were aged 18 years or older with histologically confirmed anal squamous cell carcinoma, with metastatic disease or with unresectable local recurrence; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and with at least one evaluable lesion according to the Response Evaluation Criteria in Solid Tumors (version 1.1). Chemotherapy-naive patients received either six cycles of standard DCF (75 mg/m2 docetaxel and 75 mg/m2 cisplatin on day 1 and 750 mg/m2 per day of fluorouracil for 5 days, every 3 weeks) or eight cycles of modified DCF (40 mg/m2 docetaxel and 40 mg/m2 cisplatin on day 1 and 1200 mg/m2 per day of fluorouracil for 2 days, every 2 weeks), which were administered intravenously. The choice between the standard versus modified regimens was recommended based on, but not limited to, age (≤75 years vs >75 years) and ECOG performance status (0 vs 1). The primary endpoint was investigator-assessed progression-free survival at 12 months from the first DCF cycle; for the primary endpoint to be met, at least 11 (17%) of 66 enrolled patients had to be alive without disease progression at 12 months. Efficacy and safety analyses were done in a modified intention-to-treat population, defined as all patients who were evaluable for progression at 12 months who received at least one cycle of DCF. This trial is registered at ClinicalTrials.gov, number NCT02402842, and the final results are presented here. FINDINGS: Between Sept 17, 2014, and Dec 7, 2016, we enrolled 69 patients. Of these patients, three did not receive DCF. Of the 66 patients who received treatment, 36 received the standard DCF regimen and 30 received modified DCF. The primary endpoint was met: 31 (47%) of 66 patients were alive and progression free at 12 months. 22 (61%) of 36 patients who received the standard DCF regimen and 18 (60%) of 30 patients who received the modified DCF regimen had disease progression at data cutoff. 46 (70%) of 66 patients had at least one grade 3-4 adverse event (30 [83%] of 36 in the standard DCF regimen and 16 [53%] of 30 in the modified DCF regimen). The most common grade 3-4 adverse events were neutropenia (15 [23%]; eight [22%] for standard DCF vs seven [23%] for modified DCF), diarrhoea (12 [18%]; nine [25%] vs three [10%]), asthenia (ten [15%]; eight [22%] vs two [7%]), anaemia (ten [15%]; six [17%] vs four [13%]), lymphopenia (eight [12%]; three [8%] vs five [17%]), mucositis (seven [11%]; seven [19%] vs none), and vomiting (seven [11%]; five [14%] vs two [7%]). No grade 4 non-haematological adverse events and febrile neutropenia were observed with modified DCF, whereas three (8%) grade 4 non-haematological adverse events and five (14%) cases of febrile neutropenia were reported with standard DCF. 97 serious adverse events were reported (69 in patients who received the standard DCF regimen [61 drug-related] and 28 in those given the modified DCF regimen [14 drug-related]). No treatment-related deaths were recorded. INTERPRETATION: Compared with standard DCF, modified DCF provided long-lasting response with good tolerability in patients with metastatic or unresectable locally recurrent anal squamous cell carcinoma with ECOG performance status of 0-1 in the first-line setting, and therefore could be considered as a new standard of care for these patients. Regarding the elevated risk of high-grade and serious adverse events and febrile neutropenia, standard DCF cannot be recommended in this situation. FUNDING: Besançon University Hospital and Ligue contre le cancer Grand-Est.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kim S, François E, André T, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2018. PMID: 30042063. doi:10.1016/S1470-2045(18)30321-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。